Anti-CA19-9 antibody - Amerigo Scientific

Overview
- CA19‐9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisastructure whichis synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisaand/or Lewisbblood group antigens. In normal tissues, sialyl Lewisaantigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19‐9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19‐9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is excellent for staining of formalin‐fixed, paraffin‐embedded tissues.
  
  Please contact us at for specific academic pricing.
Properties
- Host
  
  mouse
  
  Antibody Type
  
  monoclonal
  
  Isotype
  
  IgM
  
  Reactivity
  
  human
  
  Clone
  
  121SLE
  
  Immunogen
  
  Precipitin lines obtained after immuno‐diffusion using MAb 116‐NS‐19‐9 and mucins isolated from an ovarian cyst of a Lewis A+B‐patient (0Le)
  
  Conjugate
  
  Unconjugated
  
  Formulation
  
  Purified antibody diluted in Tris‐HCI buffer containing stabilizing protein and <0.1% sodium azide.
  
  Storage
  
  Store at 2-8°C for up to 1 year
  
  Regulatory Status
  
  RUO
  
  * For research use only